Five Prime Therapeutics Inc. (NASDAQ:FPRX) insider Francis Willard Sarena sold 1,710 shares of the business’s stock in a transaction on Monday, November 28th. The stock was sold at an average price of $60.14, for a total transaction of $102,839.40. Following the completion of the sale, the insider now directly owns 82,976 shares in the company, valued at approximately $4,990,176.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Francis Willard Sarena also recently made the following trade(s):

  • On Friday, November 25th, Francis Willard Sarena sold 34,654 shares of Five Prime Therapeutics stock. The stock was sold at an average price of $60.38, for a total transaction of $2,092,408.52.

Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) traded down 2.09% during mid-day trading on Wednesday, reaching $57.26. 242,808 shares of the company’s stock were exchanged. The stock has a market cap of $1.55 billion, a PE ratio of 6.40 and a beta of 4.48. Five Prime Therapeutics Inc. has a one year low of $28.01 and a one year high of $60.98. The company has a 50 day moving average price of $52.11 and a 200-day moving average price of $47.66.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Thursday, November 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by $0.21. Five Prime Therapeutics had a return on equity of 59.23% and a net margin of 64.94%. The firm earned $6.70 million during the quarter, compared to analysts’ expectations of $7.50 million. During the same quarter in the prior year, the company earned ($0.93) earnings per share. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. On average, analysts predict that Five Prime Therapeutics Inc. will post ($2.18) EPS for the current year.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

TRADEMARK VIOLATION WARNING: This story was posted by Financial Market News and is the sole property of of Financial Market News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this story can be accessed at http://www.financial-market-news.com/insider-selling-five-prime-therapeutics-inc-fprx-insider-sells-1710-shares-of-stock/1210814/.

Several brokerages recently weighed in on FPRX. Credit Suisse Group AG reissued a “buy” rating and issued a $54.00 price objective on shares of Five Prime Therapeutics in a research note on Monday, November 7th. Citigroup Inc. began coverage on shares of Five Prime Therapeutics in a research note on Tuesday, October 25th. They issued a “buy” rating and a $65.00 price objective on the stock. Leerink Swann reissued an “outperform” rating and issued a $58.00 price objective (up previously from $45.00) on shares of Five Prime Therapeutics in a research note on Monday, August 8th. Finally, Jefferies Group set a $60.00 price objective on shares of Five Prime Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 5th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $54.43.

Hedge funds have recently bought and sold shares of the stock. FMR LLC boosted its stake in Five Prime Therapeutics by 24.1% in the second quarter. FMR LLC now owns 2,817,208 shares of the company’s stock valued at $116,492,000 after buying an additional 547,808 shares during the period. Vanguard Group Inc. boosted its stake in Five Prime Therapeutics by 43.5% in the second quarter. Vanguard Group Inc. now owns 1,472,276 shares of the company’s stock valued at $60,877,000 after buying an additional 446,311 shares during the period. Acadian Asset Management LLC boosted its stake in Five Prime Therapeutics by 1.6% in the third quarter. Acadian Asset Management LLC now owns 1,111,332 shares of the company’s stock valued at $58,332,000 after buying an additional 16,964 shares during the period. BlackRock Fund Advisors boosted its stake in Five Prime Therapeutics by 7.1% in the third quarter. BlackRock Fund Advisors now owns 1,080,243 shares of the company’s stock valued at $56,702,000 after buying an additional 71,528 shares during the period. Finally, State Street Corp boosted its stake in Five Prime Therapeutics by 28.5% in the second quarter. State Street Corp now owns 1,057,836 shares of the company’s stock valued at $43,741,000 after buying an additional 234,648 shares during the period. Hedge funds and other institutional investors own 95.40% of the company’s stock.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

5 Day Chart for NASDAQ:FPRX

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.